ijbms.mums.ac.ir

## IJ**E**MS

# Osthole attenuated cytotoxicity induced by 6-OHDA in SH-SY5Y cells through inhibition of JAK/STAT and MAPK pathways

Samira Barangi <sup>1</sup>, Parisa Hosseinzadeh <sup>2</sup>, Gholamreza Karimi <sup>1, 2</sup>, Zahra Tayarani-Najaran <sup>2, 3</sup> Soghra Mehri<sup>1,2\*</sup>

<sup>1</sup> Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran <sup>2</sup> Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

<sup>3</sup> Medical Toxicology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

#### ARTICLE INFO

Article type: Original

Article history: Received: Oct 5, 2022 Accepted: Mar 15, 2023

#### Keywords:

6-ÓHDA Apoptosis JAK Kinases Mitogen-activated proteinkinase Osthole STAT3

#### **ABSTRACT**

Objective(s): Natural coumarin called osthole is regarded as a medicinal herb with widespread applications in Traditional Chinese Medicine. It has various pharmacological properties, including antioxidant, anti-inflammatory, and anti-apoptotic effects. In some neurodegenerative diseases, osthole also shows neuroprotective properties. In this study, we explored how osthole protects human neuroblastoma SH-SY5Y cells from the cytotoxicity of 6-hydroxydopamine (6-OHDA).

Materials and Methods: Using the MTT assay and DCFH-DA methods, respectively, the viability of the cells and the quantity of intracellular reactive oxygen species (ROS) were evaluated. Signal Transducers and Activators of Transcription (STAT), Janus Kinase (JAK), extracellular signal-regulated kinase 1/2 (ERK1/2), c-Jun N-terminal kinase (JNK), and caspase-3 activation levels were examined using western blotting.

*Results:* In SH-SY5Y cells, the results showed that a 24-hour exposure to 6-OHDA (200  $\mu$ M) lowered cell viability but markedly elevated ROS, p-JAK/JAK, p-STAT/STAT, p-ERK/ERK, p-JNK/JNK ratio, and caspase-3 levels. Interestingly, osthole (100  $\mu$ M) pretreatment of cells for 24 hr prevented 6-OHDA-induced cytotoxicity by undoing all effects of 6-OHDA.

Conclusion: In summary, our data showed that osthole protects SH-SY5Y cells against 6-OHDAinduced cytotoxicity by inhibiting ROS generation and reducing the activity of the JAK/STAT, MAPK, and apoptotic pathways.

Please cite this article as:

Barangi S, Hosseinzadeh P, Karimi GhR, Tayarani-Najaran Z, Mehri S. Osthole attenuated cytotoxicity induced by 6-OHDA in SH-SY5Y cells through inhibition of JAK/STAT and MAPK pathways. Iran J Basic Med Sci 2023; 26: 953-959. doi: https://dx.doi.org/10.22038/IJBMS.2023.68292.14905

#### Introduction

Currently, Parkinson's disease (PD) is considered the most common and chronic age-related neurodegenerative disorder with an effect on almost 2% of people worldwide and a prevalence of 5% over the age of 85 (1). In PD, the progressive neurological condition occurs because dopaminergic neurons selectively degenerate in the dorsal part of the substantia nigra and lead to abnormal motor control due to decreased levels of dopamine in the striatum (2). Different mechanisms, including oxidative stress, mitochondrial dysfunction, neuroinflammation, and apoptosis of dopaminergic neurons, are involved in the pathogenesis of PD (3), although the principle mechanism of initiation of PD has stayed unclear.

Several models have been used to create pathophysiological process very similar to PD. Among the different neurotoxic models of PD, the 6-hydroxydopamine (6-OHDA) is widely applied for different models of PD research (4). 6-OHDA is a crucial exogenous neurotoxin formed by dopamine oxidation and it is beneficial for the neurodegeneration studies like PD because of the induction of dopaminergic neuronal degradation (5). 6-OHDA causes dopaminergic neurotoxicity by accumulation in nigral neurons (3). One of the main mechanisms of 6-OHDA toxicity can involve the reactive oxygen species generation (ROS) during its autoxidation process. Once inside the cell, it rapidly oxidizes and generates ROS, which

impairs mitochondrial function and ultimately causes neuroinflammation and damage to dopaminergic neurons (6, 7).

Oxidative stress is an important reason for cellular toxicity in the central nervous system and promotes inflammation and apoptosis in neurodegenerative disorders like PD (8). Hence, understanding the cellular mechanisms that increase neuronal resistance to oxidative stress may prepare new avenues for PD treatment. Different molecular signaling such as JAK2/STAT3 and MAPK pathways are involved in the inflammation and apoptosis pathway regulation in PD (9, 10).

The Janus Kinase/Signal Transducers and Activators of Transcription (JAK/STAT) is a regulatory pathway, which activated by numerous cytokines, interferons, and growth factors (11), is involved in cell survival, proliferation, angiogenesis, inflammation, and apoptosis (12, 13). Aberrant activation of JAK/STAT is apparent in neuroinflammation and neurodegenerative diseases like Multiple Sclerosis, Alzheimer's, and PD (10).

The mitogen-activated protein kinase (MAPK), a serine/ threonine protein kinases superfamily, is responsible to regulate various intracellular signaling in Eukaryotes including cell differentiation and proliferation, apoptosis or survival, inflammation, and innate immunity (14). C-Jun N-terminal kinase (JNK), extracellular signal-regulated

<sup>\*</sup>Corresponding author: Soghra Mehri. Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. Tel: +98-51-31801179, Fax: +98-51-31801000, Email: MehriS@mums.ac.ir

kinases (ERK), and p38 kinase, as the main groups of MAPK, are particularly important in PD (9) and considered apoptosis factors which activate through oxidative stress (15). JNK and p38 have a substantial task in neuronal damage, and ERK over-activation is known to contribute to dyskinesia in PD striatum (16, 17). The oxidative stress in PC12 cells created by 6-OHDA leads to enhanced JNK phosphorylation and increases cell apoptosis (18, 19).

Osthole (7-Methoxy-8-(3-methylbut-2-enyl)-2-chromenone) is a coumarin derivative of a natural plant, firstly obtained from *Cnidium Monnieri* (20). It is found in various medicinal plants like the mature fruit of *C. monnieri* with an osthole high content, which is used in Traditional Chinese Medicine (21). In several experimental studies, the pharmacological effects of osthole including anticancer (22), anticonvulsant (23), hepatoprotective (24), cardiovascular protective (25), and neuroprotective (26) have been reported. Moreover, osthole has a potential anti-oxidant effect as well (27, 28). Osthole exerts physiological effects through regulation of various signaling pathways including JAK/STAT and MAP kinase which in turn modulate cell cycle regulators, transcriptional factors, and proliferation (28, 29).

Osthole indicated neuroprotection opposite to many neurodegeneration experimental models. For instance, osthole relieved the symptoms of Alzheimer's disease by attenuating inflammation and oxidative stress (30, 31). Moreover, osthole reduced oxidative stress and suppressed inflammation and apoptosis in various models of PD (26, 32). Besides, previous studies have found that osthole has a protective effect on different tissues through the regulation of MAPK and JAK/STAT3 signaling pathways (27, 33).

According to previous studies, oxidative stress, as well as apoptosis, are two main mechanisms of neurotoxicity created by 6-OHDA. Therefore, this research aimed to investigate the effect of osthole on neurotoxicity by 6-OHDA in the SH-SY5Y cell line by focusing on the activity of apoptosis, and JAK/STAT and MAPK pathways.

#### Materials and Methods

#### Materials

Osthole was obtained from Golexir Pars (Iran). 6-OHDA, MTT reagent, the fluorescent probe DCFH-DA, and penicillin-streptomycin (PS) were bought from Sigma (Germany). DMEM/F12 medium was purchased from Bio-Idea (Iran) and FBS from Gibco (USA). In this study, all used antibodies were obtained from Cell Signaling (USA).

#### Cell culture and treatment

The human neuroblastoma SH-SY5Y cell line was procured from the Pasteur Institute (Iran). The culture medium DMEM-F12 with 10% FBS along with penicillin and streptomycin were applied to culture cells and maintained in a 37 °C incubator with 95% humidity containing 5% CO<sub>2</sub> concentration and passaged at 80% confluence.

#### Cell viability assay

SH-SY5Y cells were seeded in a microplate with 96 wells (10<sup>4</sup> cells/well). Cell viability was evaluated by 6-OHDA exposure (24 hr), using an MTT assay to determine the  $IC_{50}$  value. Moreover, the effect of osthole in different concentrations on cell viability was determined after 48 hr exposure. For this purpose, cells were treated with 6-OHDA in different concentrations (50–200  $\mu$ M) and different concentrations (25–500  $\mu$ M) of osthole for 24 hr and 48 hr, respectively. Afterward, the efficacy of osthole

on cytotoxicity by 6-OHDA in SH-SY5Y cells was tested. Briefly, cells ( $10^4$  cells/well) were exposed to a different concentration of osthole ( $25-500 \mu$ M) for 24 hr and then incubated with 6-OHDA ( $200 \mu$ M; IC<sub>50</sub>). After 24 hr, the MTT solution at the final concentration of 0.5 mg/ml was poured on each well of the 96-well culture plate, and then the plate was put into a 37 °C incubator for 3 hr. After the removal of the upper culture medium, the insoluble purple formazan crystal was dissolved in 150 µl of dimethylsulfoxide (DMSO) which created a color solution, with maximum absorbance at 545 nm measurable by a microplate reader (Start Fax-2100, UK).

#### Measurement of intracellular ROS generation

To determine the amount of ROS in SH-SY5Y cells, we used the DCFH-DA (2',7'-dichlorofluorescein diacetate) method based on the Li *et al.* study with some modification (34). DCFH-DA reagent is a fluorimetric probe, which can enter the cell and deacetylate to DCFH with intracellular esterases. In the vicinity of ROS, DCFH can convert to DCF with high fluorescence. For this test,  $10^4$  SH-SY5Y cells/ well were seeded in 96-well microplates and incubated with osthole (25–500 µM) for 24 hr before treatment by 6-OHDA (200 µM). Twenty four hours later, the upper mediate was removed and 10 µM DCFH-DA was poured into the cultured cells for 30 min in a 37 °C incubator. After cells were washed with PBS, ROS generation was evaluated by the fluorescence intensity of DCF (excitation and emission wavelengths at 485 and 538 nm, respectively).

#### Western blot analysis

To investigate whether osthole had a protective effect against 6-OHDA, the expressions of proteins including caspase-3, JAK2, p-JAK2, STAT3, p-STAT3, ERK, p-ERK, JNK, and p-JNK were identified by western blot. For this purpose, About 106 SH-SY5Y cells were exposed to 6-OHDA (200  $\mu$ M) 24 hr after osthole (100  $\mu$ M). The cells were collected, and after washing with cold PBS, cells were lysed in a lysis buffer according to the instructions previously published (35). Protein concentration was ascertained by applying the Bradford assay. Then western blot test was performed regarding the protocol of our previous study (36). In a nutshell, 10 µl of samples were loaded and electrophoresed on SDS polyacrylamide gel. Proteins were transferred to PVDF membranes, which were blocked by 5% skimmed milk or BSA (Bovine Serum Albumin) for nonphosphorylated or phosphorylated proteins, respectively, at room temperature (2 hr). In the next step, the membranes were exposed to rabbit monoclonal antibodies against caspase-3 (#9665), JAK2 (#3230), p-JAK2 (#3776), STAT3 (#12640), p-STAT3 (#9145), ERK (#4695), p-ERK (#9106), JNK (#9252), p-JNK (#9255), and mouse monoclonal antibody against  $\beta$ -actin (#3700), as primary antibodies, and IgG labeled with horseradish peroxidase (anti-rabbit or anti-mouse), as secondary antibodies. To visualize protein bands, enhanced chemiluminescence was used and the bands' optical densities were measured by Gel doc (Alliance 4.7, UK). The densitometric analysis of bands was calculated by UVtec software (UK) and normalized to the related  $\beta$ -actin.

#### Statistics analysis

Prism 7.0 software (GraphPad Software, La Jolla, CA, United States) was used to analyze all data. The results were displayed as means  $\pm$  SD. Statistical comparisons were

I**JB**MS



**Figure 1.** Effect of 6-OHDA (50–300  $\mu$ M for 24 hr A), osthole (25–500  $\mu$ M for 48 hr; B), and the effect of osthole (Ost) on 6-OHDA-induced cytotoxicity for 24 hr pretreatment (C) on SH-SY5Y cell viability by the MTT assay Data are expressed as means ± SD. Data were analyzed by one-way ANOVA following the Tukey-Kramer post-test for multiple comparisons. \**P*<0.05, \*\**P*<0.01, \*\*\**P*<0.001, and \*\*\*\**P*<0.001 vs control group, #*P*<0.05 vs 6-OHDA treated group Ost: Osthole, 6OHDA: 6-ydroxydopamine

evaluated by one-way analysis of variance test (ANOVA) followed by the Tukey–Kramer *post hoc* test. All experiments were repeated in triplicate, and *P*-value <0.05 was considered the significant level.

#### Results

#### Effect of 6-OHDA on cell viability in SH-SY5Y cells

The cell cytotoxicity of the 6-OHDA was measured by MTT assay to determine the  $IC_{50}$  of 6-OHDA. As shown in Figure 1A, 6-OHDA in 24 hr treatment decreased the viability of cells in comparison to the control group.  $IC_{50}$  of 6-OHDA after 24 hr exposure was  $200 \pm 17.5 \,\mu$ M.

#### Effect of osthole on cell viability in SH-SY5Y cells

The SH-SY5Y cells were exposed to osthole at different concentrations (25–500  $\mu$ M) for 48 hr. Osthole in none of the concentrations had any significant effect on cell viability



**Figure 2.** Effect of osthole (Ost) for 24 hr pretreatment on 6-OHDAinduced ROS production in SH-SY5Y cells by using the DCFH-DA reagent Data are expressed as means  $\pm$  SD. Data were analyzed by one-way ANOVA following the Tukey-Kramer post-test for multiple comparisons. \*\**P*<0.01 vs control group, ##*P*<0.01 and ###*P*<0.0001 vs 6-OHDA group Ost: Osthole, 6OHDA: 6-ydroxydopamine

compared with the untreated group (Figure 1B).

#### Effect of osthole on 6-OHDA-induced cytotoxicity in SH-SY5Y cells

The results in Figure 1C indicated the decline in cell viability due to 6-OHDA (200  $\mu$ M) exposure for 24 hr as compared to untreated cells (*P*<0.0001), while the pretreatment with 100  $\mu$ M osthole for 24 hr markedly enhanced cell viability (*P*<0.05). In addition, no significant effect on cell viability was observed in pretreatment by other concentrations of osthole (Figure 1C).

#### Effect of osthole on ROS production by 6-OHDA in SH-SY5Y cells

6-OHDA treatment significantly enhanced the intracellular ROS in SH-SY5Y cells (P<0.01). Interestingly, the 24 hr exposure of cells with osthole (25–500  $\mu$ M) before exposure to 6-OHDA markedly inhibited ROS production. These results showed a protective effect of osthole against cytotoxicity induced by 6-OHDA (Figure 2).

## Effect of osthole and 6-OHDA on JAK2/STAT3 proteins level in SH-SY5Y cells

The results showed that 6-OHDA exposure for 24 hr significantly increased the p-JAK2/JAK2 ratio in SH-SY5Y





The blots (A and C) and the bars (B and D) exhibit the densitometry analysis of western blots for p-JAK2/JAK2 and p-STAT3/STAT3 ratio. Equal loading of proteins is illustrated by  $\beta$ -actin bands. Data are expressed as means  $\pm$  SD. Data were analyzed by one-way ANOVA following the Tukey-Kramer post-test for multiple comparisons. \**P*<0.05 and \*\**P*<0.01 vs control group, #*P*<0.05 vs 6-OHDA group

Ost: Osthole, 6OHDA: 6-ydroxydopamine



IJ**—**MS

Figure 4. Effect of osthole (Ost) for 24 hr pretreatment and 6-OHDA for 24 hr on the protein level of JNK, phospho(P)-JNK, ERK, and phospho(P)-ERK in SH-SY5Y cells

The blots (A and C) and the bars (B and D) exhibit the densitometry analysis of western blots for p-JNK/JNK and p-ERK/ERK ratio. Equal loading of proteins is illustrated by  $\beta$ -actin bands. Data are expressed as means  $\pm$  SD. Data were analyzed by one-way ANOVA following the Tukey-Kramer post-test for multiple comparisons. \*\*\*\**P*<0.0001 vs control group, ##*P*<0.01 and ####*P*<0.001 vs 6-OHDA group Ost: Osthole, 6OHDA: 6-ydroxydopamine



Figure 5. Effect of osthole (Ost) for 24 hr pretreatment and 6-OHDA for 24 hr on the protein level of caspase-3 pro and cleaved in SH-SY5Y cells The blots (A) and the bars (B) exhibit the densitometry analysis of western blots for the level of caspase-3 pro and cleaved. Equal loading of proteins is illustrated by  $\beta$ -actin bands. Data are expressed as means  $\pm$  SD. Data were analyzed by one-way ANOVA following the Tukey-Kramer post-test for multiple comparisons. \**P*<0.05 and \*\**P*<0.01 vs control group, #*P*<0.05 vs 6-OHDA group Ost: Osthole, 6OHDA: 6-ydroxydopamine

cells (P<0.01). In return, the pretreatment of the cells by osthole for 24 hr reduced the p-JAK2/JAK2 ratio in SH-SY5Y cells compared to the 6-OHDA group (P<0.05). Although the protein levels of p-STAT3 and STAT3 were separately reduced after 24 hr treatment with 6-OHDA in SH-SY5Y cells compared with control, the p-STAT3/STAT3 ratio enhanced in comparison to the untreated group (P<0.05) (Figure 3C and D). Moreover, the results demonstrated that

24 hr pretreatment of cells by osthole could decrease the p-STAT3/STAT3 ratio against the 6-OHDA group (P<0.05) (Figure 3C and D).

## Effect of osthole and 6-OHDA on the MAP kinase pathway proteins activity (JNK and ERK) in SH-SY5Y cells

The results demonstrated that after cell treatment with 6-OHDA, the p-JNK/JNK ratio elevated (P<0.0001), whereas 24 hr pretreatment with osthole attenuated the p-JNK/JNK ratio (P<0.0001). Furthermore, 24 hr exposure of 6-OHDA at a concentration of 200 µM strikingly induced the p-ERK/ERK ratio in SH-SY5Y cells in comparison to control cells (P<0.0001), while pretreatment of cells by osthole (100 µM) reduced the p-ERK/ERK ratio compared to the 6-OHDA group (P<0.01) (Figure 4C and D).

## Effect of osthole and 6-OHDA on the expression of caspase-3 in SH-SY5Y cells

As indicated in Figure 5, the caspase-3 level (pro and cleaved) enhanced in SH-SY5Y cells when exposed to 6-OHDA compared to the untreated group (P<0.05 and P<0.01, respectively), while pretreatment of osthole at a 100  $\mu$ M concentration reduced the pro and cleaved caspase-3 compared to the 6-OHDA treated cells (P<0.05).

#### Discussion

This research investigated the osthole protective effects on cytotoxicity in SH-SY5Y cells treated by 6-OHDA through JAK/STAT, MAPK, and apoptosis signaling pathway. Our results exhibited that 6-OHDA exposure induced oxidative stress and apoptosis through the increased intracellular ROS and caspase-3 levels and the phosphorylated form of JAK2, STAT3, JNK, and ERK proteins in SH-SY5Y cells. In contrast, the pretreatment of the cells with osthole reversed all changes caused by 6-OHDA in SH-SY5Y cells. It seems that osthole protects SH-SY5Y cells against 6-OHDA cytotoxicity.

Oxidative stress, apoptosis as well as inflammation lead to the loss of dopaminergic neurons which are important pathologies for PD (32). Numerous studies demonstrated that the apoptosis pathway is activated following 6-OHDAinduced ROS generation. For instance, Ramazani et al. indicated decreased cell viability, increased ROS, and apoptosis in PC12 cells treated with 6-OHDA (37). Moreover, 6-OHDA caused mitochondrial dysfunctions and enhanced the cleavage of caspase-9 and -3 in the SH-SY5Y cell line (38). Besides, G-CSF could inhibit the activated caspase-3 by 6-OHDA in dopaminergic neurons (39). On the other hand, osthole diminished oxidative stress and inflammatory cytokines in the PD mice model induced by MPTP as well as attenuating LPS-induced microglia cytotoxicity in PC12 and BV-2 cells (32). In this regard, reduced intracellular ROS, caspase-3 activity, and Bax/Bcl2 ratio induced by MPP<sup>+</sup> through pretreatment with osthole on PC12 cells has been demonstrated (26). In the current study, exposure of cells to 6-OHDA (200 µM) increased intracellular ROS production and elevated caspase-3 cleaved in SH-SY5Y cells. The protective role of osthole (100 µM) against 6-OHDA occurred through attenuating intracellular ROS level and diminished caspase-3 activity, suggesting the anti-oxidant and anti-apoptotic effect of osthole.

Several studies have illustrated that the novel inflammatory signals namely Janus Kinase/Signal Transducers and Activators of Transcription (JAK/ STAT), can be activated by LPS, TNF- $\alpha$ , IFN- $\gamma$ , and IL-6 in the brain (40) and contribute to the pathogenesis of neuroinflammatory diseases (10). For instance, the level of JAK and STAT phosphorylation was rapidly enhanced in BV-2 microglial cells in response to LPS stimulation (41, 42). The  $\alpha$ -synuclein accumulation in the brain activated microglial and produced inflammatory cytokines or chemokines through the activation of the JAK/STAT pathway in different models of PD (13). Hence, the administration of JAK1/JAK2 inhibitor, AZD1480, inhibited the activation of JAK, STAT3, and STAT1 in macrophages and microglia cells and suppressed the degeneration of dopaminergic neurons (13). Besides, the neurotoxin MPP<sup>+</sup> treatment enhanced the STAT1 expression level as well as STAT1 phosphorylation and following apoptosis in cerebellar granule neuron cells (43). Moreover, pyridone 6 as a JAK inhibitor reduced the interferon  $\beta$  neurotoxicity in SH-SY5Y cells through decreased STAT1 and STAT3 phosphorylation as well as apoptotic cell death (44).

Based on the role of the JAK/STAT pathway in brain damage, it is identified that several natural substances such as curcumin and osthole could exhibit protective effects by suppressing JAK/STAT pathways (33, 41, 45). The inflammatory cytokines secretion via LPS-stimulated BV2 cells was decreased because of osthole treatment through Nrf2 and HO1 up-regulation and NFκB signaling pathway inhibition (45). In traumatic brain injury in SH-SY5Y cells, osthole displayed anti-inflammatory and neuroprotective effects due to suppressed apoptosis and NF-kB pathways (46). Osthole also inhibited the proliferation and invasion of gallbladder cancer cells by decreasing the phosphorylation of JAK and STAT3 (33). In addition, 6-OHDA showed a neurotoxicity effect on SH-SY5Y cells by changing the level of STAT3 phosphorylation (47). In this research, results showed the increment of JAK2/STAT3 phosphorylation in SH-SY5Y cells by 6-OHDA treatment, suggesting the role of the JAK2/STAT3 pathway in the PD model. Pretreatment

of cells with osthole markedly prevented JAK2 and STAT3 phosphorylation levels in SH-SY5Y cells exposed to 6-OHDA, suggesting osthole has a neuroprotective effect in SH-SY5Y cells by suppressing the JAK2/STAT3 signaling pathway.

The MAPK signaling pathway regulates cell activity including cell viability, apoptosis, as well as inflammation in the CNS (16). ERK and JNK are a part of the MAPKs family that activate through various stimuli like cellular stress and cytokines (14). Previous studies suggested that JNK and ERK play considerable roles in the regulation of cellular processes of PD (9). Transient phosphorylation of ERK participates in enhanced cell survival but sustained ERK activation leads to neuronal and PC12 cell death (48). In this regard, it has been reported that p-ERK1/2 and p-JNK protein levels obviously increased in PD mice (49). A recent study exhibited that oxidative stress could enhance ERK phosphorylation in SH-SY5Y cells (50). Moreover, the MPP+ model of PD causes ERK and JNK activation in SH-SY5Y and SH-EP1 cells (51, 52). The neuroblastoma cells' exposure to MPP<sup>+</sup> augments α-synuclein, activates ERK, and triggers cell death (53). Besides,  $\alpha$ -synuclein provokes inflammation through JNK, ERK, and p38 activation in microglial cells (54). Hadipour et al. indicated that 6-OHDA increased ROS production, cell apoptosis, and p-JNK in PC12 cells, which were inverted by pretreatment with betanin (18). Additionally, over-activation of ERK was reported in the striatum of mice in the 6-OHDAinduced PD model (17). 6-OHDA strikingly activated the MAPK pathway through enhancement of JNK, ERK, and p38 phosphorylation in SH-SY5Y cells (38). The ERK phosphorylation and dopaminergic cell death were upregulated through oxidative stress after rotenone and 6-OHDA treatment, which induced PD progression in experimental animals (55, 56). In line with the studies mentioned above, our results illustrated the enhanced phosphorylation of JNK and ERK in SH-SY5Y cells treated with 6-OHDA.

A recent study suggested that the endogenous molecules or the plant-derived natural compounds exhibit neuroprotective effects against CNS injury by regulation of the MAPK pathway. In this regard, the beneficial neuroprotective effect of inosine against the rotenone model of PD was shown by ameliorating oxidative stress and proinflammatory cytokines along with the inhibition of ERK phosphorylation (56). Another experiment also showed that the primary astrocytes pretreatment by silibinin (a constituent of silymarin) effectively inhibited astroglial activation and decreased ERK and JNK phosphorylation before MPP+ treatment in an acute PD model induced by MPTP (57). Furthermore, the administration of C2 ceramide in LPSstimulated BV2 microglial cells suppressed microglial activation through decreased ROS production and JNK, ERK, and p38 phosphorylation (42). However, different results were reported by Chen et al. study. They showed that pretreatment of cells with osthole inhibited the enhancement of p-JNK with no effect on p-p38 but elevated ERK1/2 phosphorylation in neurons that were deficient in oxygen and glucose (27). To date, there is no earlier study, which investigated the osthole effectiveness in PD through the regulation of MAPK activity. For the first time in the current study, pretreatment of cells with osthole could



**Figure 6.** Mechanism of 6-OHDA in inducing apoptosis through JAK/ STAT and MAPK pathways in SH-SY5Y cell and the role of osthole in preventing neuronal apoptosis

decrease JNK and ERK phosphorylation in SH-SY5Y cells treated with 6-OHDA.

#### Conclusion

In summary, osthole could be able to diminish 6-OHDA cytotoxicity in SH-SY5Y cells, in part, to be mediated through the inhibition of ROS production, decreased apoptosis, and reduction of JAK/STAT and MAPK activity, which are important mechanisms in 6-OHDA neurotoxicity (Figure 6).

#### Acknowledgment

The authors are thankful to the Vice Chancellor of Research, Mashhad University of Medical Sciences, Mashhad, Iran, for financial support. The results presented in this paper were part of a student thesis.

#### **Authors' Contributions**

S B contributed to data analysis, writing, and reviewing. PH performed data handling, data analysis, and data presentation. G K designed the experiments, supervised, validated the study, and reviewed. Z TN analyzed the data, and validated the study. SM designed experiments, provided study materials and equipment, supervised, validated the study, and reviewed.

#### **Funding Informwtion**

This paper was financially supported by the Vice Chancellor of Research, Mashhad University of Medical Sciences, Mashhad, Iran (Grant Number: 970912).

#### **Conflicts of Interest**

The authors declare no conflicts of interest.

#### References

1. Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J. Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur J Epidemiol 2011; 26 Suppl 1:S1-58.

2. Reich SG, Savitt JM. Parkinson's Disease. Med Clin North Am 2019; 103:337-350.

3. Dorszewska J, Kowalska M, Prendecki M, Piekut T, Kozłowska J, Kozubski W. Oxidative stress factors in Parkinson's disease. Neural

Regen Res 2021; 16:1383-1391.

4. Rai SN, Singh P. Advancement in the modelling and therapeutics of Parkinson's disease. J Chem Neuroanat 2020; 104:1-15.

5. Salari S, Bagheri M. *In vivo, in vitro* and pharmacologic models of Parkinson's disease. Physiol Res 2019; 68:17-24.

6. Drechsel DA, Patel M. Role of reactive oxygen species in the neurotoxicity of environmental agents implicated in Parkinson's disease. Free Radic Biol Med 2008; 44:1873-1886.

7. Chia SJ, Tan EK, Chao YX. Historical Perspective: Models of Parkinson's Disease. Int J Mol Sci 2020; 21.

8. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006; 443:787-795.

9. Bohush A, Niewiadomska G, Filipek A. Role of Mitogen Activated Protein Kinase Signaling in Parkinson's Disease. Int J Mol Sci 2018; 19:1-17.

10. Yan Z, Gibson SA, Buckley JA, Qin H, Benveniste EN. Role of the JAK/STAT signaling pathway in regulation of innate immunity in neuroinflammatory diseases. Clin Immunol 2018; 189:4-13.

11. Dell'Albani P, Santangelo R, Torrisi L, Nicoletti VG, Giuffrida Stella AM. Role of the JAK/STAT signal transduction pathway in the regulation of gene expression in CNS. Neurochem Res 2003; 28:53-64.

12. Huynh J, Etemadi N, Hollande F, Ernst M, Buchert M. The JAK/ STAT3 axis: A comprehensive drug target for solid malignancies. Semin Cancer Biol 2017; 45:13-22.

13. Qin H, Buckley JA, Li X, Liu Y, Fox TH, 3rd, Meares GP, *et al.* Inhibition of the JAK/STAT Pathway Protects Against α-Synuclein-Induced Neuroinflammation and Dopaminergic Neurodegeneration. J Neurosci 2016; 36:5144-5159.

14. Kim EK, Choi EJ. Compromised MAPK signaling in human diseases: an update. Arch Toxicol 2015; 89:867-882.

15. Nakano H, Nakajima A, Sakon-Komazawa S, Piao JH, Xue X, Okumura K. Reactive oxygen species mediate crosstalk between NF-kappaB and JNK. Cell Death Differ 2006; 13:730-737.

16. Wang G, Pan J, Chen SD. Kinases and kinase signaling pathways: potential therapeutic targets in Parkinson's disease. Prog Neurobiol 2012; 98:207-221.

17. Mariani LL, Longueville S, Girault JA, Hervé D, Gervasi N. Differential enhancement of ERK, PKA and Ca(2+) signaling in direct and indirect striatal neurons of Parkinsonian mice. Neurobiol Dis 2019; 130:1-17.

18. Hadipour E, Fereidoni M, Tayarani-Najaran Z. Betanin Attenuates Oxidative Stress Induced by 6-OHDA in PC12 Cells via SAPK/JNK and PI3 K Pathways. Neurochem Res 2020; 45:395-403.

19. Ramazani E, Tayarani-Najaran Z, Fereidoni M. Celecoxib, indomethacin, and ibuprofen prevent 6-hydroxydopamine-induced PC12 cell death through the inhibition of NF $\kappa$ B and SAPK/JNK pathways. Iran J Basic Med Sci 2019; 22:477-484.

20. Zhang ZR, Leung WN, Cheung HY, Chan CW. Osthole: A Review on Its Bioactivities, Pharmacological Properties, and Potential as Alternative Medicine. Evid Based Complement Alternat Med 2015; 2015:1-9.

21. You L, Feng S, An R, Wang X. Osthole: a promising lead compound for drug discovery from a traditional Chinese medicine (TCM). Nat Prod Commun 2009; 4:297-302.

22. Shokoohinia Y, Jafari F, Mohammadi Z, Bazvandi L, Hosseinzadeh L, Chow N, *et al.* Potential Anticancer Properties of Osthol: A Comprehensive Mechanistic Review. Nutrients 2018; 10:1-16.

23. Luszczki JJ, Wojda E, Andres-Mach M, Cisowski W, Glensk M, Glowniak K, *et al.* Anticonvulsant and acute neurotoxic effects of imperatorin, osthole and valproate in the maximal electroshock seizure and chimney tests in mice: a comparative study. Epilepsy Res 2009; 85:293-299.

24. Zhang J, Xue J, Wang H, Zhang Y, Xie M. Osthole improves alcohol-induced fatty liver in mice by reduction of hepatic

oxidative stress. Phytother Res 2011; 25:638-643.

25. Chen R, Xue J, Xie ML. Reduction of isoprenaline-induced myocardial TGF- $\beta$ 1 expression and fibrosis in osthole-treated mice. Toxicol Appl Pharmacol 2011; 256:168-173.

26. Liu WB, Zhou J, Qu Y, Li X, Lu CT, Xie KL, *et al.* Neuroprotective effect of osthole on MPP+-induced cytotoxicity in PC12 cells via inhibition of mitochondrial dysfunction and ROS production. Neurochem Int 2010; 57:206-215.

27. Chen T, Liu W, Chao X, Qu Y, Zhang L, Luo P, *et al.* Neuroprotective effect of osthole against oxygen and glucose deprivation in rat cortical neurons: involvement of mitogenactivated protein kinase pathway. Neuroscience 2011; 183:203-211. 28. Zafar S, Sarfraz I, Rasul A, Shah MA, Hussain G, Zahoor MK, *et al.* Osthole: A Multifunctional Natural Compound with Potential Anticancer, Anti-oxidant and Anti-inflammatory Activities. Mini Rev Med Chem 2020; 21:2747-2763.

29. Li K, Ding D, Zhang M. Neuroprotection of Osthole against Cerebral Ischemia/Reperfusion Injury through an Anti-apoptotic Pathway in Rats. Biol Pharm Bull 2016; 39:336-342.

30. Yao Y, Gao Z, Liang W, Kong L, Jiao Y, Li S, *et al.* Osthole promotes neuronal differentiation and inhibits apoptosis via Wnt/ $\beta$ -catenin signaling in an Alzheimer's disease model. Toxicol Appl Pharmacol 2015; 289:474-481.

31. Jiao Y, Kong L, Yao Y, Li S, Tao Z, Yan Y, *et al.* Osthole decreases beta amyloid levels through up-regulation of miR-107 in Alzheimer's disease. Neuropharmacology 2016; 108:332-344.

32. Wang Y, Zhou Y, Wang X, Zhen F, Chen R, Geng D, *et al.* Osthole alleviates MPTP-induced Parkinson's disease mice by suppressing Notch signaling pathway. Int J Neurosci 2019; 129:833-841.

33. Le Zou T, Wang HF, Ren T, Shao ZY, Yuan RY, Gao Y, *et al.* Osthole inhibits the progression of human gallbladder cancer cells through JAK/STAT3 signal pathway both in vitro and in vivo. Anticancer Drugs 2019; 30:1022-1030.

34. Li Y, Shi W, Li Y, Zhou Y, Hu X, Song C, *et al.* Neuroprotective effects of chlorogenic acid against apoptosis of PC12 cells induced by methylmercury. Environmental Toxicology & Pharmacology 2008; 26:13-21.

35. Kianfar M, Nezami A, Mehri S, Hosseinzadeh H, Hayes AW, Karimi G. The protective effect of fasudil against acrylamideinduced cytotoxicity in PC12 cells. Drug Chem Toxicol 2020; 43:595-601.

36. Barangi S, Mehri S, Moosavi Z, Hayesd AW, Reiter RJ, Cardinali DP, *et al.* Melatonin inhibits Benzo(a)pyrene-Induced apoptosis through activation of the Mir-34a/Sirt1/autophagy pathway in mouse liver. Ecotoxicol Environ Saf 2020; 196:1-11.

37. Ramazani E, YazdFazeli M, Emami SA, Mohtashami L, Javadi B, Asili J, *et al.* Protective effects of Cinnamomum verum, Cinnamomum cassia and cinnamaldehyde against 6-OHDA-induced apoptosis in PC12 cells. Mol Biol Rep 2020; 47:2437-2445. 38. Ikeda Y, Tsuji S, Satoh A, Ishikura M, Shirasawa T, Shimizu T. Protective effects of astaxanthin on 6-hydroxydopamine-induced apoptosis in human neuroblastoma SH-SY5Y cells. J Neurochem 2008; 107:1730-1740.

39. Huang HY, Lin SZ, Kuo JS, Chen WF, Wang MJ. G-CSF protects dopaminergic neurons from 6-OHDA-induced toxicity via the ERK pathway. Neurobiol Aging 2007; 28:1258-1269.

40. Woo JH, Lee JH, Kim H, Park SJ, Joe EH, Jou I. Control of Inflammatory Responses: a New Paradigm for the Treatment of Chronic Neuronal Diseases. Exp Neurobiol 2015; 24:95-102.

41. Porro C, Cianciulli A, Trotta T, Lofrumento DD, Panaro MA. Curcumin Regulates Anti-Inflammatory Responses by JAK/STAT/ SOCS Signaling Pathway in BV-2 Microglial Cells. Biology 2019; 8:1-12.

42. Jung JS, Shin KO, Lee YM, Shin JA, Park EM, Jeong J, et al.

Anti-inflammatory mechanism of exogenous C2 ceramide in lipopolysaccharide-stimulated microglia. Biochim Biophys Acta 2013; 1831:1016-1026.

43. Junyent F, Alvira D, Yeste-Velasco M, de la Torre AV, Beas-Zarate C, Sureda FX, *et al.* Prosurvival role of JAK/STAT and Akt signaling pathways in MPP+-induced apoptosis in neurons. Neurochem Int 2010; 57:774-782.

44. Dedoni S, Olianas MC, Onali P. Interferon-beta induces apoptosis in human SH-SY5Y neuroblastoma cells through activation of JAK-STAT signaling and down-regulation of PI3K/ Akt pathway. J Neurochem 2010; 115:1421-1433.

45. Bao Y, Meng X, Liu F, Wang F, Yang J, Wang H, *et al.* Protective effects of osthole against inflammation induced by lipopolysaccharide in BV2 cells. Mol Med Rep 2018; 17:4561-4566. 46. Kong L, Yao Y, Xia Y, Liang X, Ni Y, Yang J. Osthole alleviates inflammation by down-regulating NF- $\kappa$ B signaling pathway in traumatic brain injury. Immunopharmacol Immunotoxicol 2019; 41:349-360.

47. Wang LL, Chen B, Xu SL. [Effect of 6-hydroxydopamine on the levels of phosphorylation of signal transduction and transcription factor 1 and 3: experiment with dopaminergic neurons]. Zhonghua Yi Xue Za Zhi 2007; 87:1048-1052.

48. Pedrosa R, Soares-da-Silva P. Oxidative and non-oxidative mechanisms of neuronal cell death and apoptosis by L-3,4-dihydroxyphenylalanine (L-DOPA) and dopamine. Br J Pharmacol 2002; 137:1305-1313.

49. Zhang Y, Xu W, Nan S, Chang M, Fan J. MicroRNA-326 Inhibits Apoptosis and Promotes Proliferation of Dopaminergic Neurons in Parkinson's Disease Through Suppression of KLK7-Mediated MAPK Signaling Pathway. J Mol Neurosci 2019; 69:197-214.

50. Mendell AL, MacLusky NJ. The testosterone metabolite  $3\alpha$ -androstanediol inhibits oxidative stress-induced ERK phosphorylation and neurotoxicity in SH-SY5Y cells through an MKP3/DUSP6-dependent mechanism. Neurosci Lett 2019; 696:60-66.

51. Gómez-Santos C, Ferrer I, Reiriz J, Viñals F, Barrachina M, Ambrosio S. MPP+ increases alpha-synuclein expression and ERK/MAP-kinase phosphorylation in human neuroblastoma SH-SY5Y cells. Brain Res 2002; 935:32-39.

52. Wang L, Yang HJ, Xia YY, Feng ZW. Insulin-like growth factor 1 protects human neuroblastoma cells SH-EP1 against MPP+induced apoptosis by AKT/GSK-3β/JNK signaling. Apoptosis 2010; 15:1470-1479.

53. Zhu JH, Gusdon AM, Cimen H, Van Houten B, Koc E, Chu CT. Impaired mitochondrial biogenesis contributes to depletion of functional mitochondria in chronic MPP+ toxicity: dual roles for ERK1/2. Cell Death Dis 2012; 3:e312.

54. Albert-Gascó H, Ros-Bernal F, Castillo-Gómez E, Olucha-Bordonau FE. MAP/ERK Signaling in Developing Cognitive and Emotional Function and Its Effect on Pathological and Neurodegenerative Processes. Int J Mol Sci 2020; 21: 1-30.

55. Hou L, Wang K, Zhang C, Sun F, Che Y, Zhao X, *et al.* Complement receptor 3 mediates NADPH oxidase activation and dopaminergic neurodegeneration through a Src-Erk-dependent pathway. Redox Biol 2018; 14:250-260.

56. El-Shamarka MEA, Kozman MR, Messiha BAS. The protective effect of inosine against rotenone-induced Parkinson's disease in mice; role of oxido-nitrosative stress, ERK phosphorylation, and A2AR expression. Naunyn Schmiedebergs Arch Pharmacol 2020; 393:1041-1053.

57. Lee Y, Chun HJ, Lee KM, Jung YS, Lee J. Silibinin suppresses astroglial activation in a mouse model of acute Parkinson's disease by modulating the ERK and JNK signaling pathways. Brain Res 2015; 1627:233-242.